A new era of diagnostics for everyone.

Leonard (Lenny) founded Vax-Immune in 2015 with a vision to innovate how we diagnose infectious diseases. As a neonatologist for 40 years, Lenny watched babies die due to misdiagnosis and after realizing that the problem lay in the way samples were being transported, “retired" to develop the first specimen transport system with specimen multiplier technology, eliminating the need for traditional transport and preventing misdiagnosis.
 
The son of Holocaust survivors, Lenny was born in a displaced persons camp in Germany, came to America and went on to graduate from West Point. After completing Airborne, Ranger and Air Defense Artillery schools, he served 24 years in the Army as an academic neonatologist, where he discovered and developed the breakthrough drug for Medimmune, which sold to Astra Zeneca for $15B. After retiring from the Army, Lenny joined the faculty at Baylor College of Medicine where he served as the Chief, Newborn Service, Texas Children’s Hospital, where his vision to build a women’s hospital became the Women’s Pavilion. While at TCH, he spearheaded the birth and care of the world’s first surviving set of octuplets and was featured in The New York Times, CNN, Today Show and in the international media.

Dr. Scher led Vax-Immune’s pre-seed and co-led its seed round.  He is Chairman and a Founder of Opertech Bio, a Philadelphia-based company that quantitatively measures taste in human subjects. Dr. Scher also serves on the board of Itarcia Therapeutics, a Boston-based company that has raised over $1B and has submitted an NDA for a GLP-1 delivery system to treat diabetes.  Additionally, he is a member of the board of Cognition Therapeutics, a Pittsburgh-based company that has a Phase-2 candidate in clinical trials in Alzheimer’s disease.

Dr. Scher received his M.D. degree from Albert Einstein College of Medicine and is certified by the American Board of Rheumatology, and the American Board of Internal Medicine.  He holds a B.S. in Chemistry from the State University of New York at Albany.

Following his medical training, Dr. Scher entered the Navy and attained the rank of Captain, USN Medical Corp. While serving in the military, Dr. Scher was a Professor of Medicine at the Uniformed Services University, Bethesda, Maryland, and head, Immunology Branch, Naval Medical Research Institute.

He served as CEO of Biosynexus where he worked with Lenny on global research initiatives in the infectious disease space.

BioSynexus was acquired for $120M.

David Allred (Dave) specializes in developing and marketing commercial and industrial properties in California, Arizona, and Texas.  

As president of Douglass Allred Company, Dave oversees a wide range of day-to-day operations and processes from site acquisition and commercial development to project financing, leasing, and marketing.   Building highly specialized teams for each project, his leadership results in a high level of involvement with City Economic Development teams and various industry leaders.  Dave currently serves on the UC San Diego Moores Cancer Center Board of Visitors. He is co-chairman of the San Diego Police Officers Widows and Orphans Charity Fund, and is an active member of the Arizona Chapter of the National Association of Industrial and Office Properties.  

He received a bachelor’s degree in Economics from the University of Southern California.